Adamas Pharma Announces Submission of ADS-5102 NDA to US FDA as Dyskinesia Treatment in PD Patients


(October 31, 2016) - Adamas Pharmaceuticals, Inc announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for ADS-5102 (amantadine hydrochloride) extended-release capsules, the company’s proprietary lead product candidate, for the potential treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. Read more

Click for a printer friendly version

Back to top